The Global Parkinson’s Disease Therapeutics Market was valued at USD 6.2 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 13.3 billion by 2034, driven by the increasing incidence of Parkinson’s disease, particularly among aging populations worldwide. As life expectancy improves, the prevalence of age-related neurodegenerative conditions like Parkinson’s is expanding rapidly. Countries across North America, Europe, and parts of the Asia-Pacific region are witnessing a notable rise in the elderly demographic, which is fueling demand for more effective treatments. Healthcare systems are responding by prioritizing therapeutic innovations and expanding access to specialized care tailored to patients with Parkinson’s disease.
The market is experiencing significant transformation as pharmaceutical advancements continue to emerge. While traditional therapies remain widely used, there’s increasing attention on alternative treatments that provide more targeted symptom control. Drug classes targeting different neural pathways are being explored to manage disease progression more effectively. Innovative delivery platforms are also making an impact. These include user-friendly systems that improve patient adherence, especially for individuals requiring long-term care. Transdermal systems, inhalation routes, and infusion therapies are popular due to their ability to deliver steady, controlled medication with fewer complications.
The Levodopa/carbidopa generated USD 3 billion in 2024. Its continued dominance is attributed to its ability to address varied motor symptoms. Enhanced formulations offering extended release and continuous delivery have helped reduce complications and provide consistent symptom management. This drug’s widespread use, affordability, and established clinical efficacy make it a cornerstone in Parkinson’s treatment across high-income and emerging economies.
Oral medications accounted for a 63.3% share in 2024. Their ease of use, cost-effectiveness, and availability make them the preferred route for patients undergoing lifelong treatment. Many of the most prescribed Parkinson’s therapies, particularly those for motor symptom relief, are developed in oral formulations. This not only improves adherence but also limits the need for hospital-based administration, making oral drugs a dominant force in the therapeutic landscape.
U.S. Parkinson’s Disease Therapeutics Market generated USD 2.3 billion in 2024. Its robust healthcare system, advanced regulatory pathways, and early access to cutting-edge treatments contribute to its leadership in Parkinson’s care. The country also benefits from strong patient support networks and collaborative R&D efforts, which promote drug discovery and accelerate the commercialization of novel therapies.
Prominent players in this industry include Teva Pharmaceutical, Newron Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, F. Hoffmann-La Roche, Kyowa Kirin, Orion Pharma, Boehringer Ingelheim, Supernus Pharmaceuticals, AbbVie, Amneal Pharmaceuticals, Novartis, Desitin Arzneimittel, Acorda Therapeutics (Merz Therapeutics), and Acadia Pharmaceuticals. To strengthen their position in the Parkinson’s disease therapeutics market, companies emphasize strategic R&D investments to develop next-generation therapies with better safety and efficacy. They pursue regulatory designations to accelerate approvals and gain early market access. Collaborations with academic institutions and biotech firms allow for diversified innovation pipelines. Expanding global distribution networks, especially in emerging economies, ensures wider medications.
This product will be delivered within 2-4 business days.
The market is experiencing significant transformation as pharmaceutical advancements continue to emerge. While traditional therapies remain widely used, there’s increasing attention on alternative treatments that provide more targeted symptom control. Drug classes targeting different neural pathways are being explored to manage disease progression more effectively. Innovative delivery platforms are also making an impact. These include user-friendly systems that improve patient adherence, especially for individuals requiring long-term care. Transdermal systems, inhalation routes, and infusion therapies are popular due to their ability to deliver steady, controlled medication with fewer complications.
The Levodopa/carbidopa generated USD 3 billion in 2024. Its continued dominance is attributed to its ability to address varied motor symptoms. Enhanced formulations offering extended release and continuous delivery have helped reduce complications and provide consistent symptom management. This drug’s widespread use, affordability, and established clinical efficacy make it a cornerstone in Parkinson’s treatment across high-income and emerging economies.
Oral medications accounted for a 63.3% share in 2024. Their ease of use, cost-effectiveness, and availability make them the preferred route for patients undergoing lifelong treatment. Many of the most prescribed Parkinson’s therapies, particularly those for motor symptom relief, are developed in oral formulations. This not only improves adherence but also limits the need for hospital-based administration, making oral drugs a dominant force in the therapeutic landscape.
U.S. Parkinson’s Disease Therapeutics Market generated USD 2.3 billion in 2024. Its robust healthcare system, advanced regulatory pathways, and early access to cutting-edge treatments contribute to its leadership in Parkinson’s care. The country also benefits from strong patient support networks and collaborative R&D efforts, which promote drug discovery and accelerate the commercialization of novel therapies.
Prominent players in this industry include Teva Pharmaceutical, Newron Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, F. Hoffmann-La Roche, Kyowa Kirin, Orion Pharma, Boehringer Ingelheim, Supernus Pharmaceuticals, AbbVie, Amneal Pharmaceuticals, Novartis, Desitin Arzneimittel, Acorda Therapeutics (Merz Therapeutics), and Acadia Pharmaceuticals. To strengthen their position in the Parkinson’s disease therapeutics market, companies emphasize strategic R&D investments to develop next-generation therapies with better safety and efficacy. They pursue regulatory designations to accelerate approvals and gain early market access. Collaborations with academic institutions and biotech firms allow for diversified innovation pipelines. Expanding global distribution networks, especially in emerging economies, ensures wider medications.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Drug Class, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Patient, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies featured in this Parkinson’s Disease Therapeutics market report include:- AbbVie
- Acadia Pharmaceuticals
- Acorda Therapeutics (Merz Therapeutics)
- Amneal Pharmaceuticals
- Boehringer Ingelheim
- Desitin Arzneimittel
- F. Hoffmann-La Roche
- Kyowa Kirin
- Newron Pharmaceuticals
- Novartis
- Orion Pharma
- Sumitomo Dainippon Pharma
- Supernus Pharmaceuticals
- Teva Pharmaceutical
- UCB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | May 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 6.2 Billion |
| Forecasted Market Value ( USD | $ 13.3 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
